Clal Biotechnology Industries elects Julian Adams as president
Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on oncology.
Until recently, Dr. Adams served as President of Research and Development at Infinity Pharmaceuticals.
Prior to joining Infinity, Dr. Adams was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he headed multiple global drug discovery programs, including the successful Velcade (bortezomib) program.
He also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in Boehringer Ingelheim, where he was credited with the discovery of Viramune (nevirapine) for HIV.
Dr. Adams has received multiple awards, holds over 40 patents and has authored more than 100 papers and book chapters in peer-reviewed journals.
Dr. Adams earned a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He received his Doctor of Science, honoris causa, from McGill University in 2012. ■
LATEST MOVES FROM Israel
- Enzymotec appoints Erez Israeli as CEO
- Teva names Yitzhak Peterburg interim president and CEO
- Radcom appoints Rami Amit as CTO
- Perion Network appoints Doron Gerstel as CEO
- Teva: Dipankar Bhattacharjee new CEO of Global Generic Medicines
More inside POST